Keywords
Abstract
References
McCall B, Findley L. Parkinson’s – answers at your fingertips. London. Class Publishing. 2010
National Institute of Health and Clinical Excellence. Parkinson’s disease: diagnosis and management in primary and secondary care. 2011 (Accessed 21/03/2014) Available from: http://www.nice.org.uk/CG035
Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson’s Disease. 2014 (Accessed 25/03/2014) Available from: http://www.sign.ac.uk/guidelines/fulltext/113/index.html
Rajput A, Rozdilsky B. Accuracy of clinical diagnosis in parkinsonism – a prospective study. Can J Neurol Sc 1991;18(3):275-8. Available from: https://doi.org/10.1017/s0317167100031814
Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology relating to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197-211. Available from: https://doi.org/10.1016/s0197-4580(02)00065-9
Ma C, Su L, Xie J, Long J, Wu P, Gu L. The prevalence and incidence of Parkinson’s disease in China: a systematic review and meta-analysis. J Neural Transm 2014;121(2):123-34. Available from: https://doi.org/10.1007/s00702-013-1092-z
Tsuboi Y. Environmental-genetic interactions in the pathogenesis of Parkinson’s disease. Exp Neurobiol 2012;21(3):123-8. Available from: https://doi.org/10.5607/en.2012.21.3.123
Wirdefeldt K, Adami H, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011;26(1):1-58. Available from: https://doi.org/10.1007/s10654-011-9581-6
Lieberman A, Williams F, Imke S, et al. Parkinson’s Disease – the complete guide for patients and caregivers. Simon and Schuster. 1993
Lubbe S, Morris HR. Recent advances in Parkinson’s disease genetics. J Neurol 2014;261(2):259-66. Available from: https://doi.org/10.1007/s00415-013-7003-2.
Martin I, Dawson V, Dawson T. Recent advances in the genetics of Parkinson’s Disease. Annu Rev Genomics Hum Genet 2011;12:301-25. Available from: https://doi.org/10.1146/annurev-genom-082410-101440
Takeda A, Mallory M, Sundsmo M, et al Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol 1998;152:367-372
Ludolph A. Comment: Braak staging in clinical practice? Neurology 2014;82(10):862 . Available from: https://doi.org/10.1212/WNL.0000000000000196
Ward CD, Duvoisin RC, Ince SE, et al. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983;33:815-24. Available from: https://doi.org/10.1212/wnl.33.7.815
Burn DJ, Mark MH, Playford ED, et al. Parkinson’s disease in twins studied with 18F-dopa and positron emission tomography. Neurology 1992;42:1894-900. Available from: https://doi.org/10.1212/wnl.42.10.1894
Sääksjärvi K, Knekt P, Männistö S, et al. Reduced risk of Parkinson’s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol 2014:1-8. Available from: https://doi.org/10.1007/s10654-014-9887-2
Liu Y, Li Y, Tang Y, et al. Vitamin D: preventive and therapeutic potential in Parkinson’s disease. Curr Drug Metab 2013;14(9):989-93. Available from: https://doi.org/10.2174/1389200211314090005
Langston J, Ballard P, Tetrud J, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80. Available from: https://doi.org/10.1126/science.6823561
Fahn S. Book Review - The case of the frozen addicts: how the solution of an extraordinary medical mystery spawned a revolution in the understanding and treatment of Parkinson’s disease. New Engl J Med 1996;335(26):2002-3. Available from: https://doi.org/10.1056/NEJM199612263352618
Parkinson’s organisation. MPTP and Drug-Induced Parkinson’s. 2007 (Accessed 01/04/2014) Available from: http://www.parkinsonsnsw.org.au
Wang A, Cockburn M, Ly T, Bronstein J, Ritz B. The association between ambient exposure to organophosphates and Parkinson’s disease risk. Occup Environ Med 2014;71(4):275-81. Available from: https://doi.org/10.1136/oemed-2013-101394
Ramalingam M, Kim S. Reactive oxygen/nitrogen species and their functional correlations in neurodegenerative stress. J Neural Transm 2012;119(8):891-910. Available from: https://doi.org/10.1007/s00702-011-0758-7
Tugwell C. Parkinson’s Disease in Focus. Pharmaceutical Press. 2008
Firestone J, Smith-Weller T, Franklin G, et al. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch Neurol 2005;62(1):91-5. Available from: https://doi.org/10.1001/archneur.62.1.91
Jiménez-Jiménez F, Mateo D, Giménez-Roldán S. Exposure to well water and pesticides in Parkinson’s disease: a case control study in the Madrid area. Mov Disord 1992;7(2):149-52. Available from: https://doi.org/10.1002/mds.870070209
Royal Pharmaceutical Society. British National Formulary 62. BMJ Group and Pharmaceutical Press. 2011
Kelley B, Duker A, Chiu P. Dopamine agonists and pathologic behaviors. Parkinsons Dis 2012;2012:1-5. Available from: https://doi.org/10.1155/2012/603631
Colledge N, Walker B, Ralston S. Davidson’s Principles & Practice of Medicine. 21st ed. Churchill Livingstone. 2010